Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.
Administration of DNA vaccines via gene gun has emerged as an important form of Ag-specific immunotherapy. The MHC CIITA is a master regulator of MHC class II expression and also induces expression of class I molecules. We reasoned that the gene gun administration of CIITA DNA with DNA vaccines employing different strategies to improve MHC I and II processing could enhance DNA vaccine potency. We observed that DC-1 cells transfected with CIITA DNA lead to higher expression of MHC I and II molecules, leading to enhanced Ag presentation through the MHC I/II pathways. Furthermore, our data suggested that coadministration of DNA-encoding calreticulin (CRT) linked to human papillomavirus (HPV) 16 E6 Ag (CRT/E6) with CIITA DNA leads to enhanced E6-specific CD8(+) T cell immune responses in vaccinated mice. In addition, coadministration of the combination of CRT/E6 DNA with CIITA DNA and DNA encoding the invariant chain (Ii) linked to the pan HLA-DR-reactive epitope (Ii-PADRE) further enhanced E6-specific CD8(+) T cell immune responses in vaccinated mice. Treatment with the combination vaccine was also shown to enhance the antitumor effects and to prolong survival in TC-1 tumor-bearing mice. Vaccination with the combination vaccine also led to enhanced E6-specific CD8(+) memory T cells and to long-term protection against TC-1 tumors and prolonged survival in vaccinated mice. Thus, our findings suggest that the combination of CIITA DNA with CRT/E6 and Ii-PADRE DNA vaccines represents a potentially effective means to combat tumors in the clinical setting.
Kim
Daejin
D
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.
Hoory
Talia
T
Monie
Archana
A
Ting
Jenny Pan-Yun
JP
Hung
Chien-Fu
CF
Wu
T-C
TC
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D017951:Antigen Presentation / Q000276:immunology; D019470:Biolistics / Q000379:methods*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D037282:Calreticulin / Q000235:genetics / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D005434:Flow Cytometry; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D000949:Histocompatibility Antigens Class II / Q000378:metabolism; D017780:Malaria Vaccines / Q000235:genetics / Q000276:immunology*; D051379:Mice; D009374:Neoplasms, Experimental / Q000517:prevention & control; D009687:Nuclear Proteins / Q000235:genetics / Q000276:immunology*; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins / Q000235:genetics / Q000276:immunology; D015534:Trans-Activators / Q000235:genetics / Q000276:immunology*; D014162:Transfection; D019444:Vaccines, DNA / Q000276:immunology*
D000276:Adjuvants, Immunologic; D037282:Calreticulin; D019496:Cancer Vaccines; C068651:E6 protein, Human papillomavirus type 16; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; C083728:MHC class II transactivator protein; D017780:Malaria Vaccines; D009687:Nuclear Proteins; D009856:Oncogene Proteins, Viral; C401223:PADRE 45; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins; D015534:Trans-Activators; D019444:Vaccines, DNA; C059731:oncogene protein E7, Human papillomavirus type 16